WASHINGTON, D.C. -- The U.S. Food and Drug Administration (FDA) announced Friday the launch of a new “green list” import alert aimed at blocking unsafe foreign versions of GLP-1 drug ingredients from entering the U.S.

The move is the latest step by the agency to protect patients as demand surges for medications like semaglutide and tirzepatide.

Semaglutide and tirzepatide are prescription medicines used to treat type 2 diabetes and, in some cases, chronic weight management. Semaglutide is sold under brand names like Ozempic and Wegovy, while tirzepatide is sold as Mounjaro and Zepbound. Both drugs work by mimicking natural hormones in the body that help control blood sugar and appetite, which can also lead to weight loss. Tirzepatide is slightly different because it acts on two hormone

See Full Page